Our technology platform and drug discovery approach is focused on novel ways to reduce "cellular cholesterol burden" (CCB™). Factors that can contribute to CCB include 1) elevated plasma cholesterol reflected in circulating low density lipoproteins and remnant lipoproteins, which provide cholesterol to the peripheral tissues or 2) reduced capacity of the cell to remove free excess cholesterol. While process 1 results from sub-optimal clearance of lipoprotein cholesterol by liver, process 2 can result from defect in liver as well as peripheral tissues. CCB can result in cell malfunction and depending on the cell of origin can lead to disease conditions such as atherosclerosis, diabetes and Alzheimer's. Research at Reddy US has identified two novel druggable targets, a clearance promoting enzyme (CPE) and a transcription factor (CPTF), whose modulation has profound impact on the way liver cells clear lipoprotein cholesterol.